Literature DB >> 24953860

Dietary intake and plasma metabolomic analysis of polyunsaturated fatty acids in bipolar subjects reveal dysregulation of linoleic acid metabolism.

Simon J Evans1, Rachel N Ringrose2, Gloria J Harrington2, Peter Mancuso3, Charles F Burant4, Melvin G McInnis2.   

Abstract

Polyunsaturated fatty acids (PUFA) profiles associate with risk for mood disorders. This poses the hypothesis of metabolic differences between patients and unaffected healthy controls that relate to the primary illness or are secondary to medication use or dietary intake. However, dietary manipulation or supplementation studies show equivocal results improving mental health outcomes. This study investigates dietary patterns and metabolic profiles relevant to PUFA metabolism, in bipolar I individuals compared to non-psychiatric controls. We collected seven-day diet records and performed metabolomic analysis of fasted plasma collected immediately after diet recording. Regression analyses adjusted for age, gender and energy intake found that bipolar individuals had significantly lower intake of selenium and PUFAs, including eicosapentaenoic acid (EPA) (n-3), docosahexaenoic acid (DHA) (n-3), arachidonic acid (AA) (n-6) and docosapentaenoic acid (DPA) (n-3/n-6 mix); and significantly increased intake of the saturated fats, eicosanoic and docosanoic acid. Regression analysis of metabolomic data derived from plasma samples, correcting for age, gender, BMI, psychiatric medication use and dietary PUFA intake, revealed that bipolar individuals had reduced 13S-HpODE, a major peroxidation product of the n-6, linoleic acid (LA), reduced eicosadienoic acid (EDA), an elongation product of LA; reduced prostaglandins G2, F2 alpha and E1, synthesized from n-6 PUFA; and reduced EPA. These observations remained significant or near significant after Bonferroni correction and are consistent with metabolic variances between bipolar and control individuals with regard to PUFA metabolism. These findings suggest that specific dietary interventions aimed towards correcting these metabolic disparities may impact health outcomes for individuals with bipolar disorder.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Atypical antipsychotics; Eicosadienoic acid; Hydroperoxy octadecadienoic acid; Omega-3; Omega-6

Mesh:

Substances:

Year:  2014        PMID: 24953860      PMCID: PMC4127886          DOI: 10.1016/j.jpsychires.2014.06.001

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  38 in total

1.  Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients.

Authors:  J K Yao; S Leonard; R D Reddy
Journal:  Schizophr Res       Date:  2000-03-16       Impact factor: 4.939

2.  The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998.

Authors:  C E Begley; J F Annegers; A C Swann; C Lewis; S Coan; W B Schnapp; L Bryant-Comstock
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

Review 4.  Bioactive eicosanoids: role of prostaglandin F(2α) and F₂-isoprostanes in inflammation and oxidative stress related pathology.

Authors:  Samar Basu
Journal:  Mol Cells       Date:  2010-11-18       Impact factor: 5.034

5.  Differential effects of antipsychotic medications on polyunsaturated fatty acid biosynthesis in rats: Relationship with liver delta6-desaturase expression.

Authors:  Robert K McNamara; Ronald Jandacek; Therese Rider; Patrick Tso; Allyson Cole-Strauss; Jack W Lipton
Journal:  Schizophr Res       Date:  2011-03-31       Impact factor: 4.939

Review 6.  Omega-3 fatty acids for bipolar disorder.

Authors:  P Montgomery; A J Richardson
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

7.  Nutrition and exercise behavior among patients with bipolar disorder.

Authors:  Amy M Kilbourne; Dana L Rofey; John F McCarthy; Edward P Post; Deborah Welsh; Frederic C Blow
Journal:  Bipolar Disord       Date:  2007-08       Impact factor: 6.744

Review 8.  The two faces of the 15-lipoxygenase in atherosclerosis.

Authors:  Jonas Wittwer; Martin Hersberger
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2007-09-14       Impact factor: 4.006

9.  An economic evaluation of manic-depressive illness--1991.

Authors:  R J Wyatt; I Henter
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1995-08       Impact factor: 4.328

10.  Fats and factors: lipid profiles associate with personality factors and suicidal history in bipolar subjects.

Authors:  Simon J Evans; Alan R Prossin; Gloria J Harrington; Masoud Kamali; Vicki L Ellingrod; Charles F Burant; Melvin G McInnis
Journal:  PLoS One       Date:  2012-01-13       Impact factor: 3.240

View more
  17 in total

1.  Low unesterified:esterified eicosapentaenoic acid (EPA) plasma concentration ratio is associated with bipolar disorder episodes, and omega-3 plasma concentrations are altered by treatment.

Authors:  Erika Fh Saunders; Aubrey Reider; Gagan Singh; Alan J Gelenberg; Stanley I Rapoport
Journal:  Bipolar Disord       Date:  2015-10-01       Impact factor: 6.744

2.  An Untargeted Metabolomics Analysis of Antipsychotic Use in Bipolar Disorder.

Authors:  Kyle J Burghardt; Simon J Evans; Kristen M Wiese; Vicki L Ellingrod
Journal:  Clin Transl Sci       Date:  2015-08-27       Impact factor: 4.689

3.  Valnoctamide, which reduces rat brain arachidonic acid turnover, is a potential non-teratogenic valproate substitute to treat bipolar disorder.

Authors:  Hiren R Modi; Kaizong Ma; Lisa Chang; Mei Chen; Stanley I Rapoport
Journal:  Psychiatry Res       Date:  2017-04-26       Impact factor: 3.222

4.  Adolescents with or at ultra-high risk for bipolar disorder exhibit erythrocyte docosahexaenoic acid and eicosapentaenoic acid deficits: a candidate prodromal risk biomarker.

Authors:  Robert K McNamara; Ronald Jandacek; Patrick Tso; Thomas J Blom; Jeffrey A Welge; Jeffrey R Strawn; Caleb M Adler; Stephen M Strakowski; Melissa P DelBello
Journal:  Early Interv Psychiatry       Date:  2015-10-20       Impact factor: 2.732

Review 5.  Polyunsaturated fatty acids and recurrent mood disorders: Phenomenology, mechanisms, and clinical application.

Authors:  Erik Messamore; Daniel M Almeida; Ronald J Jandacek; Robert K McNamara
Journal:  Prog Lipid Res       Date:  2017-01-06       Impact factor: 16.195

6.  Familial risk for bipolar disorder is not associated with impaired peroxisomal function: Dissociation from docosahexaenoic acid deficits.

Authors:  Robert K McNamara; Ann B Moser; Richard I Jones; Ronald Jandacek; L Rodrigo Patino; Jeffrey R Strawn; Stephen M Strakowski; Melissa P DelBello
Journal:  Psychiatry Res       Date:  2016-10-25       Impact factor: 3.222

7.  The gut microbiome composition associates with bipolar disorder and illness severity.

Authors:  Simon J Evans; Christine M Bassis; Robert Hein; Shervin Assari; Stephanie A Flowers; Marisa B Kelly; Vince B Young; Vicky E Ellingrod; Melvin G McInnis
Journal:  J Psychiatr Res       Date:  2016-12-10       Impact factor: 4.791

8.  Meta-analysis of erythrocyte polyunsaturated fatty acid biostatus in bipolar disorder.

Authors:  Robert K McNamara; Jeffrey A Welge
Journal:  Bipolar Disord       Date:  2016-04-18       Impact factor: 6.744

9.  Bipolar disorder moderates associations between linoleic acid and markers of inflammation.

Authors:  Ya-Wen Chang; Shervin Assari; Alan R Prossin; Laura Stertz; Melvin G McInnis; Simon J Evans
Journal:  J Psychiatr Res       Date:  2016-10-27       Impact factor: 4.791

10.  Plasma linoleic acid partially mediates the association of bipolar disorder on self-reported mental health scales.

Authors:  Simon J Evans; Shervin Assari; Gloria J Harrington; Ya-Wen Chang; Charles F Burant; Melvin G McInnis
Journal:  J Psychiatr Res       Date:  2015-06-14       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.